Interstitial nephritis in a patient taking sorafenib.
Izzedine
Hassane
H
Brocheriou
Isabelle
I
Rixe
Olivier
O
Deray
Gilbert
G
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000494:pharmacology; D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D018572:Disease-Free Survival; D006801:Humans; D007249:Inflammation; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000188:drug therapy; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D009395:Nephritis, Interstitial / Q000139:chemically induced*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000494:pharmacology; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib